Company intelligence / Profile preview
Augustine Therapeutics
Leuven, Belgiumaugustinetx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Augustine Therapeutics is developing selective HDAC6 inhibitors with a novel non-hydroxamate, non-hydrazide producing chemotype that avoids the limitations of previous approaches. Their lead program AGT-100216 is advancing toward clinical trials for Charcot-Marie-Tooth Disease.
- Therapeutic areas
- EndocrinologyCardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Eli Lilly and Company
Beyond the preview
Go deeper on Augustine Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Augustine Therapeutics.